Oramed Pharmaceuticals
ORMP
71 hedge funds and large institutions have $25.5M invested in Oramed Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 23 increasing their positions, 23 reducing their positions, and 19 closing their positions.
508% more call options, than puts
Call options by funds: $3.68M | Put options by funds: $605K
0% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 23
6.98% less ownership
Funds ownership: 17.12% → 10.15% (-7%)
14% less capital invested
Capital invested by funds: $29.6M → $25.5M (-$4.11M)
19% less funds holding
Funds holding: 88 → 71 (-17)
79% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$635K |
| 2 |
Man Group
London,
United Kingdom
|
+$574K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$524K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$435K |
| 5 |
JSMC
Jess S. Morgan & Co
Los Angeles,
California
|
+$414K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$4.39M |
| 2 |
Two Sigma Investments
New York
|
-$3.86M |
| 3 |
Two Sigma Advisers
New York
|
-$2.84M |
| 4 |
Renaissance Technologies
New York
|
-$1.65M |
| 5 |
E
Ergoteles
New York
|
-$1.62M |
ORMP Hedge Fund Activity: Q3 2022 in Review
71 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q3 2022, worth a combined $25.5M — down 14% from $29.6M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of ORMP and 4 opened new positions — a net loss of 15 holders — while 23 trimmed existing stakes and 23 added.
The largest buyer was Walleye Capital, opening a new position worth an estimated $635K. The largest seller was Citadel Advisors, cutting an estimated $4.39M.
- 71 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q3 2022, down from 88 in Q2 2022.
- Funds reported $25.5M of Oramed Pharmaceuticals stock for Q3 2022, down 14% quarter-over-quarter.
- 4 funds opened new Oramed Pharmaceuticals positions in Q3 2022 and 19 closed out, a net change of -15 holders.
- The largest Oramed Pharmaceuticals buyer in Q3 2022 was Walleye Capital, an estimated $635K added.
- The largest Oramed Pharmaceuticals seller in Q3 2022 was Citadel Advisors, an estimated $4.39M sold.
Based on aggregated 13F filings for Q3 2022.